Biosimilars are a classification of biologic medicines that are similar to currently available biologic therapies known as originators. Having successfully delivered complex originator biologics for almost 40 years, today Biogen is one of only a handful of companies with the leading manufacturing capabilities and the deep scientific expertise needed to produce consistently high-quality biosimilars of advanced biologics. By bridging our heritage of scientific innovation with an opportunity to reduce healthcare costs and increase access to biologics, developing biosimilars is a compelling way in which we can make a difference in the lives of the patients we serve.

Through a joint venture with Samsung Biologics, called Samsung Bioepis Co., Biogen’s biosimilar therapies are marketed in the European Union.